MedPath

Takeda Pharmaceutical Company Ltd

🇯🇵Japan
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

Phase 2
Completed
Conditions
Norovirus
Interventions
Biological: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Drug: 0.9% sodium chloride (saline)
First Posted Date
2016-01-22
Last Posted Date
2020-05-18
Lead Sponsor
Takeda
Target Recruit Count
320
Registration Number
NCT02661490
Locations
🇺🇸

Johnson County Clin-Trials, Lenexa, Kansas, United States

🇺🇸

University of Rochester, Rochester, New York, United States

🇺🇸

Simon Williamson Clinic, Birmingham, Alabama, United States

and more 7 locations

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Phase 3
Completed
Conditions
Uterine Fibroids
Interventions
First Posted Date
2016-01-13
Last Posted Date
2019-03-22
Lead Sponsor
Takeda
Target Recruit Count
281
Registration Number
NCT02655237

A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids

Phase 3
Completed
Conditions
Uterine Fibroids
Interventions
First Posted Date
2016-01-13
Last Posted Date
2019-03-22
Lead Sponsor
Takeda
Target Recruit Count
65
Registration Number
NCT02655224

Lubiprostone for the Treatment of Chronic Idiopathic Constipation

Phase 3
Completed
Conditions
Constipation
Interventions
Drug: Placebo
First Posted Date
2016-01-08
Last Posted Date
2018-08-13
Lead Sponsor
Takeda
Target Recruit Count
204
Registration Number
NCT02651155

Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

Phase 4
Completed
Conditions
Crohn's Disease
Interventions
Drug: Placebo
First Posted Date
2015-12-15
Last Posted Date
2019-11-19
Lead Sponsor
Takeda
Target Recruit Count
34
Registration Number
NCT02630966
Locations
🇫🇷

Hopital de Brabois, Vandoeuvre les Nancy, France

🇫🇷

Hopital l'Archet II, Nice Cedex 3, France

🇳🇱

Academic Medical Center, Amsterdam, Netherlands

and more 15 locations

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 3
Terminated
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2015-12-14
Last Posted Date
2015-12-14
Lead Sponsor
Takeda
Target Recruit Count
401
Registration Number
NCT02629848

A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

Phase 3
Completed
Conditions
Colitis, Ulcerative
Crohn's Disease
Interventions
First Posted Date
2015-12-02
Last Posted Date
2025-04-03
Lead Sponsor
Takeda
Target Recruit Count
746
Registration Number
NCT02620046
Locations
🇧🇪

AZ Groeninge - Kennedylaan, Kortrijk, Belgium

🇺🇸

L & L Research Choices, Inc., Miami, Florida, United States

🇧🇷

Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil

and more 298 locations

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Phase 2
Recruiting
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
First Posted Date
2015-11-26
Last Posted Date
2024-11-13
Lead Sponsor
Takeda
Target Recruit Count
70
Registration Number
NCT02616302
Locations
🇲🇽

SMIQ S. de R.L. de C.V., Queretaro, Mexico

🇺🇸

Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, United States

🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 24 locations

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

Phase 4
Withdrawn
Conditions
Weight Regain Post Bariatric Surgery
Interventions
First Posted Date
2015-11-26
Last Posted Date
2016-04-08
Lead Sponsor
Takeda
Registration Number
NCT02616315

A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children

Phase 2
Recruiting
Conditions
Erosive Esophagitis
Interventions
First Posted Date
2015-11-26
Last Posted Date
2023-08-18
Lead Sponsor
Takeda
Target Recruit Count
76
Registration Number
NCT02615184
Locations
🇺🇸

Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, United States

🇺🇸

D&H National Research Centers, Miami, Florida, United States

🇺🇸

Gastrointestinal Associates, PA, Flowood, Mississippi, United States

and more 24 locations
© Copyright 2025. All Rights Reserved by MedPath